Tuesday November 24 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Nabi Biopharmaceuticals

NABI Biopharmaceuticals are a biopharmaceutical company focused on the development of products that address unmet medical needs in the areas of nicotine addiction and infectious disease. We leverage our experience and knowledge in powering the human immune system to target serious medical conditions in these areas. Our lead products in development are NicVAX® [ Nicotine Conjugate Vaccine ], an innovative and proprietary investigational vaccine for treatment of nicotine addiction and prevention of smoking relapse, and StaphVAX® [ Staphylococcus aureus Vaccine ], a new pentavalent vaccine designed to prevent S.aureus infections including those infections caused by the most dangerous antibiotic-resistant strains of S.aureus .

NicVAX is an investigational vaccine based on patented technology. Nicotine, a small molecule, can cross the blood-brain barrier and reach specific receptors in the brain, thereby leading to the highly addictive pleasure sensation experienced by smokers and users of nicotine products. NicVAX is designed to stimulate the immune system to produce antibodies that bind to nicotine. A nicotine molecule attached to an antibody is too large to cross the blood-brain barrier, and thus is unable to reach the receptors in the brain and trigger pleasure sensations. In November 2007, we announced the successful completion of a Phase IIb “proof-of-concept” clinical trial for our NicVAX development program. The Phase IIb study showed statistically significant rates of smoking cessation and continuous long-term smoking abstinence at 6 and 12 months for subjects injected with NicVAX as compared with subjects injected with a placebo.

StaphVAX is an investigational vaccine based on patented technology, including technology that we have licensed on an exclusive basis from the National Institutes of Health, or NIH. We are developing StaphVAX for use in patients who are at high risk of S.aureus infection and who are able to respond to a vaccine by producing their own antibodies.

NicVAX and StaphVAX will require additional development, including preclinical testing and human studies for StaphVAX and additional human testing for NicVAX as well as regulatory approvals, before we can market them. We are continuing to develop NicVAX and StaphVAX while we search for partners who will assist in the further development and commercialization of these products.


Contact Details:
12276 Wilkins Ave
Rockville
MD
20852
United States of America
Tel:301-255-6803
Fax:301-770-3097
Email:gfries@nabi.com
WWW:

www.nabi.com/




Loading...

Recent Publications by Nabi Biopharmaceuticals:

Controversies in the management of hyperphosphatemia in patients with end-stage renal disease.
Quantum information theory establishes the ultimate limits on...
4th May, 2006
Medical Affairs Department, Nabi Biopharmaceuticals, Rockville, MD, USA. Manag Care. 2006 Mar;15(3 Suppl):5-8.
Safety and immunogenicity of a booster dose of Staphylococcus aureus types 5 and 8 capsular polysaccharide conjugate vaccine (StaphVAX) in hemodialysis patients.
StaphVAX, an unadjuvanted, bivalent vaccine composed of Staphylococcus...
25th May, 2005
WW Karakawa Microbial Pathogenesis Laboratory, Nabi Biopharmaceuticals, Vaccine. 2004 Dec 16;23(5):656-63.
DOI Direct Link
Development of StaphVAX, a polysaccharide conjugate vaccine against S. aureus infection: from the lab bench to phase III clinical trials.
Staphylococcus aureus is the most common nosocomial pathogen and is...
28th April, 2004
NABI Biopharmaceuticals, 12280 Wilkins Avenue, Rockville, MD 20852, USA. Vaccine. 2004 Feb 17;22(7):880-7.
DOI Direct Link

Press Releases on Nabi Biopharmaceuticals:

BioPortfolio Logo
Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications 26th October, 2009 Reportlinker
NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Immunotherapies and Vaccines for Nontraditional
New Report Just Published: World Multiple Myeloma Therapeutics Market Report 7th July, 2009 Reportlinker
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Multiple Myeloma Therapeutics Market http://www.reportlinker.com/p0119496/World
New Report Just Published: World Hepatitis C Virus And Therapeutics Market Report 7th July, 2009 Reportlinker
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue. World Hepatitis C Virus And Therapeutics Market http://www.reportlinker.com/p0119497/World
Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer 11th November, 2008 Cynvec LLC
NEW YORK, Nov. 11 /PRNewswire/ -- Cynvec LLC, a privately-held biopharmaceutical company focused on developing novel cancer therapies that harness the apoptotic ability of the Sindbis viral vector

BioNews Results for Nabi Biopharmaceuticals:

Nabi Biopharmaceuticals Announces Third Quarter 2009 Financial
GlobeNewswire via MSN Money:  Nov 5 2009 9:28PM Matching: nabi biopharmaceuticals
Nabi Biopharmaceuticals Completes Sale of PentaStaph to GlaxoSmithKline PLC
MDLinx:  Nov 5 2009 11:16AM Matching: nabi biopharmaceuticals
Nabi Biopharmaceuticals Announces Withdrawal of Biotest's Indemnification Claim
World Market Media:  Nov 4 2009 12:46AM Matching: nabi biopharmaceuticals
Nabi Biopharmaceuticals Completes Sale of PentaStaph(TM) to GlaxoSmithKline PLC
Stockwatch:  Nov 4 2009 2:33PM Matching: nabi biopharmaceuticals
Nabi Biopharmaceuticals Completes Sale of PentaStaph(TM) to GlaxoSmithKline PLC
World Market Media:  Nov 4 2009 6:01PM Matching: nabi biopharmaceuticals
Promote your company here: BioNewsCast - Press Release Distribution

View more Nabi Biopharmaceuticals news.

Nabi Biopharmaceuticals Patents:

US Patent No.Title
7547712 Methods for decreasing the toxic effects of nicotine on fetuses in pregnant women
6875445 Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption
6936258 Staphylococcus antigen and vaccine
7030101 Compositions of .beta.-glucans and specific antibodies
7247502 Hapten-carrier conjugates for treating and preventing nicotine addiction

View more Nabi Biopharmaceuticals patents.

Nabi Biopharmaceuticals (NABI) Financial information Links from Barchart

NABI Quote from from Barchart.com
NABI Chart from from Barchart.com
NABI Profile from from Barchart.com
NABI Opinion from from Barchart.com

View more Nabi Biopharmaceuticals finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 560 times since April 2007, the link to the organisation's website has been followed 75 times

Recent Search Terms used to find this page: nicvax stonebanks | cynvec virus | who is producing nicvax | staphVAX 2009 | biopharmaceuticals | .

Search for more companies in Rockville

Search for more companies in MD



This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for Nabi Biopharmaceuticals

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.